Maria Carmen Riesco-Martínez

Suggest Changes
  • Citations Per Year
Learn More
PURPOSE Patients with unresectable wild-type KRAS metastatic colorectal cancer benefit from fluoropyrimidines (FP), oxaliplatin (O), irinotecan (I), bevacizumab (Bev), and epithelial growth factor(More)
  • 1